Quarter Comparison
Revenue
Gross Margin
Net Margin
EPS (Diluted)
Income Statement
Cash Flow Statement
Balance Sheet
Earnings Release
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx ● Discussions with FDA advance toward expected marketing authorization for GraftAssureDx ● FDA completes current portion of substantive review in a timely manner ● Fa
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx ● Discussions with FDA advance toward expected marketing authorization for GraftAssureDx ● FDA completes current portion of substantive review in a timely manner ● Favorable Medicare reimbursement policy issued in July significantly increases GraftAssureDx surveillance testing opportunity ● Strong head-to-head data drive kitted customer interest NASHVILLE, TN., August 10, 2026 — Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its first quarter results: Fellow shareholders, We continue to be encouraged by progress toward our most important priority, which is to attain regulatory authorization of GraftAssureDx. In late July, the FDA completed the current phase of its substanti...
Source
Exhibit EX-99.1
0001493152-26-036863
Filed August 10, 2026 at 8:10 PM UTC. The figures above are from the audited statements, not from this release.